Biotechnology pioneer, BARD1 Life Sciences Limited (ASX: BD1) has the potential to diagnose lung and ovarian cancers at an early stage. The company, committed to transforming the early detection and prevention of cancer, has built a proprietary technology ‘BARD1’ that could help improve the survival rate of people diagnosed with lung or ovarian cancers.
As per the government statistics, lung cancer has been the major cause of cancer death in Australia in view of data that unveiled 8,410 deaths in year 2016 alone. It was also estimated by the Government that about 12,741 new cases of lung cancer were to be diagnosed in 2018 and this would lead to estimated deaths of 9,198 people due to tumour formation in the tissue of one or both lungs.
It’s evident to say that the revolutionary technology of BARD1 in the field of life sciences could bring down the number to a considerably low level. The company’s medical technology BARD1 is developed on the basis of novel tumour markers with therapeutic applications and potential diagnosis of multiple cancers.
The use of non-invasive diagnostics test methods sets the company aside as it helps to secure safe and convenient blood samples at an affordable cost to people. For instance, under BARD1-Lung test, the company measures multiple BARD1 autoantibodies in the blood which are then combined into a cancer score by using a proprietary diagnostic algorithm that eventually results into the identification of the presence or absence of lung cancer.
Proprietary BARD1-Lung test even has the potential to test high-risk individuals that have a history of smoking, the primary source of lung cancer, before symptoms occur.
Besides Lung cancer, the company sharply focuses on ovarian cancer. It develops and commercialises BARD1- Ovarian blood test technology that identifies the existence of ovarian cancer at an early stage. With the use of a proprietary diagnostic algorithm, BARD1-Ovarian also has the potential to screen risk of malignancy in women with pelvic masses.
Headquartered in Western Australia, BARD1 could now be seen moving towards the development of new field- Breast Cancer. Recently, the company has secured the positive results in the development of breast cancer diagnosis technology as the BARD1-Breast cancer test showed high diagnostic accuracy for detection of breast cancer with 70% sensitivity and 88% accuracy.
Following the successful results, the company stated: “The new BARD1-Breast cancer test will use the same BARD1 autoantibody test methodology and Luminex instrumentation as the BARD1-Ovarian cancer test enabling fast development and parallel clinical testing.”
The company’s cancer vaccine program conducted during the half-year ended 31 December 2018 has reported encouraging results showing delayed tumour growth in a malignant mesothelioma mouse model.
Most importantly, BARD1 has been awarded new patents in two key patent families protecting the BARD1- Ovarian and BARD1-Breast cancer tests in the USA, and the BARD1-Lung cancer test in China.
BD1 last traded at $0.016 with the market capitalisation of $15.91 million as at 15 March 2019. The stock has posted attractive performance in the past with as high as 48.68% returns in the past six months.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.